Thu Sep 19 08:23:33 UTC 2024: ## Institutional Investors Show Growing Interest in Akero Therapeutics

**New York, NY** – Akero Therapeutics (NASDAQ: AKRO), a company developing treatments for serious metabolic diseases, has seen significant interest from institutional investors in recent quarters. Rhumbline Advisers, a prominent investment firm, increased its stake in Akero by 30.3% during the second quarter, bringing its total holdings to 107,338 shares valued at $2,518,000.

Other notable investors also increased their positions in Akero, including:

* **Quarry LP:** Increased its stake by 40% in Q4 2023.
* **Ameritas Investment Partners Inc.:** Increased its stake by 20% in Q1 2024.
* **Russell Investments Group Ltd.:** Increased its stake by a whopping 2,366% in Q1 2024.
* **Principal Financial Group Inc.:** Increased its stake by 15.6% in Q1 2024.
* **ProShare Advisors LLC:** Increased its stake by 24.4% in Q1 2024.

This flurry of investment activity suggests growing confidence in Akero’s future prospects. The company’s lead product candidate, efruxifermin (EFX), is currently in Phase 3 clinical trials for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Analysts are also optimistic about Akero’s trajectory. Cantor Fitzgerald, HC Wainwright, and Wolfe Research have all issued “buy” or “outperform” ratings on the stock. MarketBeat currently gives the company a “Moderate Buy” rating with an average price target of $41.13.

While insider sales have been reported recently, overall insider ownership remains high at 7.94%, further indicating positive sentiment towards the company.

Akero Therapeutics is a company to watch as it navigates the final stages of clinical trials for its promising treatment for MASH. With strong institutional backing and positive analyst sentiment, AKRO stock could be poised for significant growth in the coming months.

Read More